4 recruiting, 2 completed, 1 active not recruiting. 4 Phase 2, 3 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Active not recruiting 1 |
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Uma Borate: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Recruiting | Uma Borate | 70 | 2026-10-01 | 2026-08-27 |
| Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia Axatilimab, Azacitidine, Biospecimen Collection - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Uma Borate | 49 | 2024-08-02 | 2026-08-27 |
| SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Gilteritinib - Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement | Phase 1 | Recruiting | Uma Borate | 30 | 2024-02-20 | 2026-05-14 |
| Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Canakinumab - Clonal Cytopenia of Undetermined Significance | Phase 2 | Recruiting | Uma Borate | 110 | 2023-02-06 | 2026-01-02 |
| Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome Azacitidine, Quality-of-Life Assessment, Questionnaire Administration - Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome | Phase 2 | Active not recruiting | Uma Borate | 33 | 2022-06-23 | 2026-05-14 |
| TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia Azacitidine, Dubermatinib - Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Early Phase 1 | Completed | Uma Borate | 3 | 2020-11-05 | 2023-02-06 |
| Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, Daunorubicin Hydrochloride - Acute Myeloid Leukemia | Phase 1 | Completed | Uma Borate | 21 | 2019-03-13 | 2026-05-15 |
Leukemia, Myeloid, Acute (4) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1)
Biopsy (4) · Specimen Handling (4) · Azacitidine (3) · Cytarabine (2) · Daunorubicin (1) · Gemtuzumab (1) · Hydroxyurea (1) · Leukapheresis (1) · Stem Cell Transplantation (1) · X-Rays (1) · axatilimab (1) · canakinumab (1) · dubermatinib (1) · gilteritinib (1) · midostaurin (1)
United States (7)
Uma M Borate, MD (2) · Uma M Borate, MD, MS (2) · Uma M Borate, MBBS, MD, MSc (1)